Astellas Pharma (ALPMF) Gets a Buy from Goldman Sachs
In a report released today, from Goldman Sachs maintained a Buy rating on Astellas Pharma, with a price target of Yen2,250.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Currently, the analyst consensus on Astellas Pharma is a Moderate Buy with an average price target of $12.43.
The company has a one-year high of Yen2,134.00 and a one-year low of Yen1,243.50. Currently, Astellas Pharma has an average volume of 8.35M.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas Pharma Revises FY2025 Financial Forecasts Upward
- Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
- Astellas Pharma’s ASP4396 Study: A Potential Game-Changer for Solid Tumors
- Astellas Pharma’s ASP3021 Study: A New Hope for AMD Patients?
- Astellas Pharma’s Peficitinib Study: Key Insights for Investors
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.